Clinical Trials · NCT06120556
Efficacy of Glucagon-like Peptide-1 Receptor Agonists According to Type 2 Diabetes Subtypes
- Phase
- N/A
- Recruitment status
- Completed
- Sponsor
- Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
- Enrollment
- 130
- Start date
- Jun 2023
- Locations
- 1 site, Italy
- Primary endpoint
- Difference in HbA1c change from baseline (%) among SIDD, SIRD, MARD, MOD subtypes